Posted inCampaigning Community News International Medicines News PrEP Prevention Research Treatment Gilead to support generic lenacapavir in low-income nations Posted by By Tom Hayes-Isaacs 2024-10-08 Earlier this month, Gilead Sciences announced that it had signed non-exclusive, royalty-free voluntary licensing agreements…
Posted inCampaigning International News Prevention Activists demand global access to HIV prevention drug Posted by By Tom Hayes-Isaacs 2024-09-24 HIV and sexual health activists protested today at Gilead Sciences' London Office demanding the company…
Posted inNews PrEP Prevention Research Twice-yearly lenacapavir 89% more effective than Truvada Posted by By Tom Hayes-Isaacs 2024-09-24 New data from the PURPOSE 2 study shows that twice-yearly lenacapavir is 89% more effective…
Posted inHealthcare International News PrEP Prevention PrEP approved to prevent HIV in Japan Posted by By Tom Hayes-Isaacs 2024-08-30 Japan has approved the use of Truvada (TDF/FTC), sold by Gilead Sciences under the brand name Truvada, as PrEP for the prevention of HIV in the country.